Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05309200 · ClinicalTrials.gov registry record · Phase 2
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
A Phase 2 study of Acute Kidney Injury and Cirrhosis, sponsored by Ocelot Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 20
- Study locations
NCT05309200: Completed Phase 2 study of Acute Kidney Injury and Cirrhosis, sponsored by Ocelot Bio.
NCT05309200 is a Phase 2 study of Acute Kidney Injury and Cirrhosis that has completed, run by Ocelot Bio. The registered enrollment target is 47 participants, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05309200, a Phase 2 study of Acute Kidney Injury and Cirrhosis, has completed, sponsored by Ocelot Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 20
- Study locations
Study Summary
OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG OCE-205
Study Locations (20)
California
- Keck Medical Center of USC - Los Angeles
- University of California, San Francisco Liver Clinic - San Francisco
- Stanford Hospital - Stanford
Minnesota
- M Health Fairview University of Minnesota Medical Center - Minneapolis
- Mayo Clinic - Rochester
Texas
- Baylor University - Dallas
- CHI St Luke's Health Baylor College of Medicine Medical Center - Houston
Arizona
- Mayo Clinic - Phoenix - Phoenix
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- Tampa General Medical Group - Tampa
Georgia
- Piedmont Atlanta Hospital - Atlanta
Illinois
- Northwestern Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 2 |
What the finished NCT05309200 record still lists
NCT05309200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05309200 names 20 study sites across 16 states, led by California, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT05309200 about?
NCT05309200 is a clinical study titled "A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury". OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Pa...
What is the current status of trial NCT05309200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2022-04-28. Estimated completion is 2023-10-13.
What conditions does trial NCT05309200 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Cirrhosis, Ascites, Hepatorenal Syndrome.
What interventions are being tested in trial NCT05309200?
The interventions under investigation include: Placebo (DRUG), OCE-205 (DRUG).
Who is sponsoring clinical trial NCT05309200?
This trial is sponsored by Ocelot Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05309200 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05309200's enrollment target sits among peer trials
47 59th of 74 higher than 16 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI